Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.49 |
| ▸ | HTR2A | P28223 | 4/20 | 0.49 |
| ▸ | HTR2B | P41595 | 4/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4024343 | 0.99 | HTR2C (0.48) | HTR2CHTR2AHTR2BSIGMAR1MEN1 | |
| SCHEMBL4028957 | 0.91 | HTR2C (0.46) | HTR2CHTR2AHTR2BSIGMAR1MEN1 | |
| SCHEMBL4621680 | 0.83 | HTR2C (0.54) | HTR2CHTR2AHTR2BSIGMAR1MEN1 | |
| SCHEMBL3829775 | 0.81 | CYP2C19 (0.55) | ACHE | |
| SCHEMBL4032377 | 0.79 | HTR2A (0.49) | HTR2CHTR2AHTR2BMCHR1 | |
| SCHEMBL4027212 | 0.78 | HTR2C (0.53) | HTR2CHTR2AHTR2BSIGMAR1MCHR1 | |
| SCHEMBL14221051 | 0.74 | SIGMAR1 (0.62) | HTR2CHTR2AHTR2BSIGMAR1MEN1 | |
| SCHEMBL4023275 | 0.73 | MEN1 (0.57) | HTR2CHTR2AHTR2BSIGMAR1MEN1 | |
| Hydrochloric Acid SCHEMBL4623932 | 0.73 | SIGMAR1 (0.61) | HTR2CHTR2AHTR2BSIGMAR1MEN1 | |
| SCHEMBL6200574 | 0.72 | MEN1 (0.55) | HTR2CHTR2AHTR2BSIGMAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497265-B1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2009-02-18 | — | — | EP | disclosed |
| EP-1497265-B1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2009-02-18 | — | — | EP | disclosed |
| EP-1599445-B1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LTD (GB) | 2008-04-02 | — | — | EP | disclosed |
| US-20060205788-A1 | Compounds having activity at 5ht2c receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | US | disclosed |
| EP-1599445-A1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2005-11-30 | — | — | EP | disclosed |
| EP-1497265-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004078718-A1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2004-09-16 | — | — | WO | disclosed |
| WO-2003089409-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205788-A1 | Compounds having activity at 5ht2c receptor and uses thereof | HTR2C, HTR7, HTR3C | HTR2C 1/4885HTR2A 13/4885HTR2B 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.